Plain-English Summary
Exenatide AUD studied exenatide in Treatment-seeking adults with alcohol use disorder receiving cognitive-behavioral therapy. Exenatide did not significantly reduce heavy drinking days overall compared with placebo.
Key Findings
- Exenatide did not significantly reduce heavy drinking days overall compared with placebo.
- Exenatide attenuated alcohol cue reactivity in reward-related brain areas.
- Exploratory analyses suggested reduced heavy drinking days and total alcohol intake in participants with BMI greater than 30.
Limitations
- Primary drinking endpoint was not significant overall.
- Subgroup findings should be treated as exploratory.
- The trial used exenatide, not semaglutide or tirzepatide.
Why It Matters
Reduction in heavy drinking days
Viral Vitalism Verdict
Useful evidence, bounded by design: Primary drinking endpoint was not significant overall.